Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences has commenced treatment of the fifth patient in its Phase 1 clinical trial for CAR-T therapy targeting ovarian cancer. This trial, conducted in partnership with Moffitt Cancer Center, enrolls female patients with recurrent ovarian cancer unresponsive to at least two prior therapies. The trial aims to identify the maximum tolerated dose of T-cells targeting the follicle stimulating hormone receptor (FSHR), which is uniquely expressed on ovarian cells. Safety was confirmed in the first cohort of three patients, and the second cohort, including the fifth patient, receives triple the dose of engineered T-cells. According to Dr. Amit Kumar, Anixa's Chairman and CEO, the trial continues to show that the therapy is safe and well-tolerated, offering hope for an effective CAR-T treatment for solid tumors.
Anixa Biosciences, a clinical-stage biotechnology company, announced an expanded partnership with Cleveland Clinic to develop novel cancer vaccines targeting various cancer types. The vaccines focus on a unique scientific approach by immunizing against 'retired' proteins found in cancer cells, aiming to destroy cancer cells as they arise and prevent tumor formation. Collaborating on breast cancer and ovarian cancer vaccines, the partnership aims to lead in cancer research with promising preliminary data.
Anixa Biosciences, Inc. CEO Dr. Amit Kumar was featured on the 'Target: Cancer Podcast' by oncologist Dr. Sanjay Juneja, discussing 'The Vaccine That Could End Breast Cancer.' The podcast highlighted Anixa's unique vaccine technology aiming to prevent the growth and spread of cancer cells. Dr. Juneja praised the potential impact of Anixa's vaccines on cancer treatment.
Anixa Biosciences, a clinical-stage biotechnology company, will participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024. The CEO will present the company's cancer treatment and prevention programs, including a breast cancer vaccine in Phase 1 trials and a CAR-T cell therapy for ovarian cancer in Phase 1 trials. The company has a capital efficient business model with strong positive data and no debt.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
